Nanobiotix Halts Trading to Finalize €75 M Follow-On Offering Pricing
Nanobiotix halted trading of ordinary shares on Euronext Paris to finalize allocations and pricing for the €75 million follow-on offering. The €75 million offering includes US ADSs and European ordinary shares with pre-funded warrants, with 50–60% of proceeds for Nanoprimer, 30–40% for corporate needs and under 10% for JNJ-1900 development.
1. Trading Halt Announcement
Nanobiotix requested a temporary trading halt of its ordinary shares on Euronext Paris at the market open to enable confirmation of investor allocations and announcement of pricing for its follow-on offering. The halt commenced at 9:00 a.m. CEST and will remain in effect until these steps are completed.
2. Structure of the Global Offering
The transaction consists of a US public offering of American Depositary Shares (ADSs) representing ordinary shares, and an international offering of ordinary shares alongside pre-funded warrants for qualified investors in Europe and select other markets, excluding the United States and Canada.
3. Offering Size and Allocation of Proceeds
The total size of the global offering is €75 million (approximately $87 million USD). Proceeds are earmarked 50–60% to advance the Nanoprimer platform, 30–40% for general corporate purposes and under 10% for development of JNJ-1900.
4. Next Steps and Implications
Upon conclusion of the allocation process, Nanobiotix will announce the final pricing and share count, after which trading will resume. This financing round will bolster cash reserves but may introduce dilution for existing shareholders ahead of clinical and commercial milestones.